Montelukast

證據等級: L5

預測適應症: 5 個

Montelukast: From Asthma to Bronchitis

One-Sentence Summary

Montelukast (Singulair) is a selective cysteinyl leukotriene receptor 1 (CysLT1) antagonist, globally approved since 1998 for asthma and allergic rhinitis, though it is currently not registered in the Philippines. The TxGNN model predicts it may be effective for Bronchitis — with the most compelling mechanistic relevance for eosinophilic bronchitis and post-transplant bronchiolitis obliterans syndrome (BOS) — supported by 23 clinical trials and 20 publications currently available in evidence databases.

Quick Overview

Item	Content
Original Indication	Not registered in the Philippines; globally approved for asthma and allergic rhinitis (US FDA, 1998)
Predicted New Indication	Bronchitis (including eosinophilic bronchitis and bronchiolitis obliterans)
TxGNN Prediction Score	99.95%
Evidence Level	L2
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Montelukast is a selective oral CysLT1 receptor antagonist that blocks cysteinyl leukotrienes (LTC4, LTD4, LTE4) — potent lipid mediators produced by mast cells, eosinophils, and basophils that drive bronchoconstriction, mucus hypersecretion, and eosinophilic airway inflammation. Its core pharmacology targets the arachidonic acid cascade in airway tissues, and its efficacy in asthma has been proven across FDA, EMA, and multiple other regulatory approvals worldwide since 1998.

The TxGNN “bronchitis” prediction spans a heterogeneous spectrum of bronchial inflammatory conditions. The mechanistic link is strongest for two specific subtypes: non-asthmatic eosinophilic bronchitis (NAEB), where CysLT-driven eosinophilic airway inflammation occurs without the variable airflow obstruction of asthma, making CysLT1 blockade a directly applicable therapeutic strategy; and bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic stem cell or lung transplantation, where elevated leukotriene B4 (LTB4) has been detected in bronchoalveolar lavage fluid and the FAM regimen (Fluticasone + Azithromycin + Montelukast) has become a recognized therapeutic approach for new-onset BOS. In both subtypes, the CysLT pathway is mechanistically implicated in the pathology Montelukast was designed to suppress.

The overlap between asthma and eosinophilic bronchitis is well-established pharmacologically — both involve CysLT-mediated eosinophilic airway inflammation, making Montelukast’s extrapolation mechanistically sound. The connection to acute viral bronchiolitis (e.g., RSV-induced) is more indirect, relying on transiently elevated CysLT levels during viral infection rather than a primary eosinophilic mechanism, and current RCT data in this subgroup have produced inconsistent results. The “bronchitis” label therefore encompasses subtypes with very different evidence quality, and interpretation must account for this heterogeneity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01307462	Phase 2	Completed	36	FAM triple therapy (Fluticasone + Azithromycin + Montelukast) for new-onset BOS after stem cell transplant; primary endpoint was treatment failure (≥10% FEV1 decline); established FAM as a frontline post-transplant BOS treatment
NCT01211509	Phase 4	Completed	30	Randomized, double-blind, placebo-controlled trial directly evaluating Montelukast for BOS after lung transplantation; assessed whether Montelukast slows chronic allograft rejection
NCT00656058	Phase 2	Completed	25	Multi-institutional prospective study of Montelukast for bronchiolitis obliterans after SCT/BMT; foundational repurposing evidence demonstrating CysLT1 blockade relevance in post-transplant lung disease
NCT03072849	N/A	Completed	23	Early spirometric detection and FAM therapy for BOS prevention in pediatric HSCT; evaluated whether early FAM intervention preserves lung function and prevents BOS progression
NCT01121016	Phase 4	Unknown	63	Montelukast add-on to inhaled budesonide for non-asthmatic eosinophilic bronchitis (NAEB); measured cough visual analogue score and airway eosinophilia as primary endpoints
NCT02479074	Phase 4	Completed	49	feNO-guided differential diagnosis of chronic cough; Montelukast vs prednisolone for eosinophilic airway inflammation, using 24-hour objective cough counting
NCT00524693	N/A	Completed	51	Double-blind, placebo-controlled trial of Montelukast in acute RSV bronchiolitis; assessed clinical progression and cytokine profiles with elevated CysLT levels confirmed at baseline
NCT01370187	N/A	Completed	146	Montelukast for acute bronchiolitis and post-bronchiolitis viral-induced wheezing in infants 3–12 months; evaluated treatment response and recurrent wheezing reduction
NCT04613180	Phase 4	Unknown	100	Effectiveness of Montelukast sodium in treatment and prevention of recurrent obstructive bronchitis in children aged 1–7 years; 80 subjects randomized into two groups
NCT05293132	Phase 2/3	Completed	90	Montelukast vs CoQ10 in ICU sepsis patients; provides indirect evidence for Montelukast’s anti-inflammatory effects in acute pulmonary inflammatory settings

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38485149	2024	Clinical Practice Guideline	European Respiratory Journal	ERS/EBMT joint guidelines on management of pulmonary chronic graft-versus-host disease in adults; formally positions Montelukast within the BOS treatment algorithm
38504551	2024	Narrative Review	Ther Adv Respir Dis	Comprehensive mechanistic review of Montelukast’s therapeutic potential in BOS after lung/HSCT; discusses CysLT1 blockade, NF-κB, and TGF-β pathways in BOS pathogenesis
26475726	2016	Phase 2 Trial Report	Biol Blood Marrow Transplant	FAM regimen in 36 HCT patients with new-onset BOS; stabilization of FEV1 decline observed; supports FAM as active intervention strategy
27229850	2016	Controlled Study	Respiratory Research	Budesonide/formoterol + Montelukast + NAC vs standard corticosteroids for HSCT-associated BOS; comparative lung function and symptom outcome data
25563311	2015	RCT	Chinese Medical Journal	Montelukast add-on to budesonide in NAEB: statistically significant improvement in cough quality of life and airway eosinophilia reduction vs budesonide monotherapy
35114411	2022	Phase 2 Trial Report	Transplant Cell Ther	Prospective Phase II trial of Montelukast for BOS after HCT; simultaneously investigated BOS pathogenesis and CysLT activity markers at the molecular level
20976161	2010	RCT	PLoS ONE	Randomized trial of fish oil vs Montelukast (alone and combined) on airway inflammation and bronchoconstriction; confirms Montelukast’s direct anti-inflammatory action in eosinophilic airway conditions
28545478	2017	Animal Study	J Cardiothorac Surg	LTB4 and Montelukast in a rat model of transplantation-related bronchiolitis obliterans; demonstrated LTB4’s pathophysiological role in chronic rejection and Montelukast’s attenuation effect

Philippines Market Information

Montelukast currently has no registered products in the Philippines. There are no active FDA Philippines licenses on record, the drug is not commercially available through local regulatory channels, and no dosage forms have been approved for any indication. Any clinical use or new indication development would require a full initial registration application — including submission of a complete safety, efficacy, and quality dossier meeting FDA Philippines standards — before market authorization can be granted.

Safety Considerations

Please refer to the package insert for safety information.

Of particular clinical importance: the US FDA issued a Boxed Warning in 2020 on neuropsychiatric adverse events associated with Montelukast — including agitation, aggression, hallucinations, depression, sleep disturbances, and suicidal thinking/behavior — observed especially in pediatric patients. This signal is substantiated by multiple systematic reviews and large cohort studies in the available evidence base (PMID 37758273, PMID 30905424, PMID 39836401). Any indication expansion, particularly in pediatric bronchitis or recurrent wheezing populations, must incorporate a formal neuropsychiatric risk-benefit evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic and clinical rationale for Montelukast in eosinophilic bronchitis and post-transplant BOS is supported by multiple completed Phase 2/4 trials (L2), but the broad “bronchitis” label encompasses highly heterogeneous subtypes with significantly different evidence quality — from well-supported BOS to inconclusive RSV bronchiolitis. Additionally, the drug has no Philippines registration and key safety data (package insert warnings and contraindications per FDA Philippines) has not been collected, precluding near-term clinical deployment without completing a full regulatory pathway.

To proceed, the following is needed:

Narrow the clinical target: Prioritize one of three specific subtypes — (a) non-asthmatic eosinophilic bronchitis (NAEB), (b) post-HSCT/lung transplant BOS, or (c) recurrent obstructive bronchitis in children — each with a distinct development strategy and evidence threshold
Philippines FDA registration pathway: Initiate regulatory pre-consultation and assess requirements for initial product registration, including identification of a suitable local sponsor or marketing authorization holder
Complete safety data collection: Obtain full package insert safety information, with specific documentation of the FDA 2020 Boxed Warning on neuropsychiatric events and its implications for the target patient population
BOS-focused meta-analysis: Pool efficacy data from NCT01307462, NCT00656058, and NCT01211509 to determine whether combined evidence reaches the L1 threshold for the BOS subtype specifically
Pharmacoeconomic assessment: Evaluate cost-effectiveness in the Philippines healthcare context, particularly for transplant-eligible patient populations where BOS represents an unmet clinical need
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.